Vaccine comprising rsv antigen and cpg oligonucleotide
CA 2370708 A1 · Owner: Smithkline Beecham Biologicals S.A. · Inventors: Deschamps, Marguerite
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to a vaccine formulation comprising a Respiratory Syncytial Virus (RSV) antigen and an immunostimulatory CpG oligonucleotide to , methods of preparing the vaccine formulation and to its use in medicine. Further antigens may be included to provide new combination vaccines for administration to children, to adults and to the elderly.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 17, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 17, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 17, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.